10/12/2004
ReGen Therapeutics Plc (‘ReGen’) a Company developing a treatment for Alzheimer’s Disease, today announces that it is giving its annual update to investors and analysts at 4.30pm on Monday 13th December, 2004.
At the Presentation the Executive Directors will review ReGen’s three businesses:
1. Drug development.
2. Nutraceutical development.
3. Conducting clinical trials.
The science behind ReGen’s projects will be reviewed by:
Professor Marian Kruzel – University of Texas Medical Branch.
Professor Michael Stewart and Dr Duncan Banks of the Open University.
No new financial information on ReGen will be presented at this meeting other than in relation to an estimated expenditure and cash burn for the current financial year.
A further press release relating to the presentation will be made on Monday 13th December 2004.
For further information, please contact:
Andrew Marshall
Marshall Robinson Roe
Tel No 020 7960 6007